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Weight gainMost atypical antipsychotic drugs (APDs), e.g. risperidone (RIS), producemore extensive blockade of brain sero-
tonin (5-HT)2A than dopamine (DA) D2 receptors. This distinguishes them from typical APDs, e.g. haloperidol
(HAL). Our objective was to test the hypothesis that augmentation of low doses of RIS or HAL (2 mg/day) with
pimavanserin (PIM), a selective 5-HT2A inverse agonist, to enhance 5-HT2A receptor blockade, can achieve
efﬁcacy comparable to RIS, 6 mg/day, but with lesser side effects. In a multi-center, randomized,
double-blind, 6 week trial, 423 patients with chronic schizophrenia experiencing a recent exacerbation of
psychotic symptoms were randomized to RIS2mg+placebo (RIS2PBO), RIS2mg+PIM20mg (RIS2PIM),
RIS6mg+PBO (RIS6PBO), HAL2mg+PBO (HAL2PBO), or HAL2mg+PIM20mg (HAL2PIM). Improvement
in psychopathology was measured by the PANSS and CGI-S. The reduction in PANSS Total Score with
RIS2PIM at endpoint was signiﬁcantly greater than RIS2PBO:−23.0 vs.−16.3 (p=0.007), and not signif-
icantly different from the RIS6PBO group: −23.2 points. The percentage of patients with ≥20% improve-
ment at day 15 in the RIS2PIM group was 62.3%, signiﬁcantly greater than the RIS6PBO (42.1%; p=0.01)
and the RIS2PBO groups (37.7%; p=0.002). Weight gain and hyperprolactinemia were greater in the
RIS6PBO group than the RIS2PIM group but there was no difference in extrapyramidal side effects (EPS).
HAL2PBO and HAL2PIM were not signiﬁcantly different from each other in efﬁcacy but HAL2PIM had less
EPS at end point. Both HAL groups and RIS6PBO showed equal improvement in psychopathology at end-
point, indicating HAL 2 mg/day is effective to treat an acute exacerbation in chronic schizophrenia patients.
In conclusion, a sub-effective RIS dose combined with PIM to enhance 5-HT2A receptor blockade provided
faster onset of action, and at endpoint, equal efﬁcacy and better safety, compared to standard dose RIS.
These results support the conclusion that 5-HT2A receptor blockade is a key component of the action of
some atypical APDs and can reduce EPS due to a typical APD.
© 2012 Elsevier B.V. Open access under CC BY-NC-ND license. 1. Introduction
Schizophrenia is characterized by positive and negative symptoms,
cognitive impairment and major deﬁcits in social and work function
(Buchanan, 2007; Harvey and Bellack, 2009; Kalkstein et al., 2010;
Keshavan et al., 2011). Antipsychotic drugs (APDs) are classiﬁed as ‘typ-
ical’ or ‘atypical’ based on their liability to cause extrapyramidal symp-
toms (EPS) at clinically effective doses (Meltzer, 2000). Both classes ofd as a poster at the American
Raton, Florida, in December,
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Meltzer).
-NC-ND license. drugs treat positive symptoms in approximately 70% of patients with
non-treatment resistant schizophrenia (Leucht et al., 2000; Lieberman
et al., 2005; Meltzer and Bobo, 2006). Metabolic side effects, e.g. weight
gain, hyperlipidemia, and type II diabetes mellitus, are the principal
risks associated with some atypical APDs (Morrato et al., 2009;
Meltzer et al., 2011a), while tardive dyskinesia, which is associated
with increasedmortality, cognitive impairment, and other adverse con-
sequences, is much more common and severe with typical APDs (Byne
et al., 1998; Margolese et al., 2005; Dean and Thuras, 2009). Thus, side
effect minimization is or should be a central consideration in choice of
APDs (Velligan et al., 2009).
There is extensive preclinical and clinical evidence that 5-HT2A re-
ceptor antagonism contributes to the efﬁcacy and reduced motoric
side effects of some atypical APDs (Meltzer et al., 1989, 2003, 2012;
Ichikawa et al., 2002; Weiner et al., 2003; Li et al., 2004; Meltzer
145H.Y. Meltzer et al. / Schizophrenia Research 141 (2012) 144–152and Huang, 2008), although this has been disputed (Kapur and Seeman,
2001). 5-HT2A receptors are strategically located on glutamatergic,
GABAergic, cholinergic, serotonergic and dopaminergic neurons where
they are generally excitatory (Nocjar et al., 2002; Lüttgen et al., 2005;
Meltzer and Huang, 2008). The atypical APDs vary greatly in their afﬁn-
ities for other receptors which affect a wide range of brain functions,
e.g. DA D1, 5-HT2C, 5-HT6, 5-HT7, muscarinic, α1- and α2- adrenergic
and H1-receptors. Some, but not all, of these receptor-mediated ef-
fects contribute to their efﬁcacy and tolerability (Schotte et al.,
1996; Kroeze et al., 2003; Meltzer and Huang, 2008; Meltzer et al.,
2012). The shared pharmacology of typical APDs is limited to D2 recep-
tor antagonism (Creese et al., 1976) which predicts efﬁcacy and
mechanism-driven side effects such as EPS and plasma prolactin in-
creases. Selective 5-HT2A inverse agonists such as SR43460B and
M100907 produce greater improvement than placebo in some mea-
sures of psychopathology in acutely psychotic patientswith schizophre-
nia, one of many indications of the potential beneﬁcial contribution of
5-HT2A receptor blockade to the efﬁcacy of those APDs which achieve
5-HT2A receptor blockade in vivo (Meltzer et al., 2004; Snigdha et al.,
2010; Preda et al., 2011). Ritanserin, a mixed 5-HT2A/2C antagonist
(Schreiber et al., 1994), was reported to improve positive and negative
symptoms in a four week trial in 10 acutely psychotic patients with
schizophrenia (Wiesel et al., 1994). The combination of ritanserin
and RIS6mg/day in a placebo-controlled trial in chronic schizophre-
nia patients with prominent negative symptoms showed signiﬁcant-
ly greater improvement in negative symptoms between weeks 6 and
8, but not at earlier periods. There was no difference between the
two groups with regard to improvement in positive symptoms or
general psychopathology (Akhondzadeh et al., 2008).
Pimavanserin (PIM), another selective 5-HT2A inverse agonist
(Vanover et al., 2006), has been reported to reduce delusions and hal-
lucinations in a placebo-controlled trial in patients with Parkinson's
disease psychosis (Meltzer et al., 2010b). PIM has been shown to en-
hance the efﬁcacy in rats of HAL to inhibit amphetamine-induced hy-
peractivity. PIM also synergistically interacted with HAL and RIS to
suppress hyperactivity induced by the N-methyl-d-aspartate receptor
antagonist (5R,10S)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]
cyclohepten-5,10-imine hydrogen maleate (MK-801). These are
two accepted models of antipsychotic activity. Furthermore, PIM at-
tenuated HAL- and RIS-induced catalepsy and hyperprolactinemia
(Gardell et al., 2007). PIM was more effective to potentiate RIS
than HAL with regard to attenuation of catalepsy.
On the basis of these considerations, we tested the hypothesis that the
addition of PIM to what was predicted to be sub-effective doses of the
atypical APD, risperidone (RIS), or the typical APD, haloperidol (HAL),
(McEvoy et al., 1986, 1991; Marder and Meibach, 1994), would lead to
clinical efﬁcacy comparable to that of RIS, 6 mg/day, a dose believed to
be effective in the majority of non-treatment resistant schizophrenia pa-
tients, and at the same time, produce less severe weight gain, EPS, and
serum prolactin elevations (Nyberg et al., 1995, 1999; Lieberman et al.,
2005). Based on PET data (Nordstrom et al., 2008), a 20 mg dose of PIM
was chosen to ensure maximal occupancy of the brain 5-HT2A receptors.
Thus, the current study investigated the effect of co-therapy with
PIM (20 mg QD) and a presumptive suboptimal dose of RIS (1 mg
BID; RIS2PIM) or HAL (2 mg QD; HAL2PIM) as representatives of atyp-
ical and typical APDs, respectively, in patients with chronic schizophre-
nia experiencing an acute exacerbation of psychotic symptoms.
Explorative objectives were to compare both RIS2PIM and HAL2PIM to
RIS6PBO in terms of efﬁcacy and safety.
2. Methods
2.1. Study design
None-ﬁrst episode patients who met DSM-IV criteria for schizo-
phrenia experiencing a recent exacerbation of psychotic symptomswere recruited from 11 sites in the United States (n=240) and
seven in Brazil (n=183) for this randomized, multicenter, double-
blind, six week trial to test the effectiveness and safety of combining
PIMwith suboptimal doses of RIS and HAL. The sample size was based
upon a power analysis. The protocol was approved by the appropriate
institutional review boards in both countries. Written informed con-
sent was obtained from each patient following a full explanation of
study procedures, risks and beneﬁts. Raters were trained and quali-
ﬁed for PANSS assessment. The study was conducted according to
globally accepted standards of good clinical practice (as deﬁned in
the International Conference on Harmonisation [ICH] E6 Guideline
for Good Clinical Practice [GCP], 1 May 1996), in agreement with
the latest revision of the Declaration of Helsinki regulations.
Patients were enrolled over a 14 month period. Following a 2-to
14-day screening period, eligible patients were randomized to one of
ﬁve treatment arms:1) RIS6mg (3 mg BID) plus placebo (RIS6PBO);
2) RIS2mg (1 mg BID) plus placebo (RIS2PBO); 3) RIS2mg (1 mg BID)
plus PIM20mg (RIS2PIM); 4) HAL2mg plus PIM20mg (HAL2PIM); and
5) HAL2mg plus placebo (HAL2PBO), and treated on an in-patient and
subsequently out-patient basis for up to 6 weeks. All current psychotro-
pic medications were discontinued at randomization.
The primary objective of this study was to determine if RIS2PIM or
HAL2PIM would demonstrate antipsychotic efﬁcacy superior to that
of RIS2PBO or HAL2PBO, respectively. Secondary objectives were to:
1) determine whether RIS2PIM or HAL2PIM would demonstrate efﬁ-
cacy against negative symptoms when compared with RIS2PBO or
HAL2PBO, respectively; and 2) assess the safety and tolerability of
RIS2PIM and HAL2PIM in schizophrenia subjects. Exploratory objec-
tives were to compare the RIS2PIM and HAL2PIM combinations to
RIS6PBO (standard treatment) with regard to efﬁcacy and safety.
2.2. Patient selection
Men or women 18 to 65 years old who met DSM-IV criteria for
schizophrenia, with a recent acute exacerbation of psychotic symp-
toms, a history of ≥two episodes, and who were not considered to
be treatment resistant were eligible to participate in the study. A
baseline Positive and Negative Syndrome Scale (PANSS; Kay et al.,
1987) score≥65 and a score of four or more on two of the four
PANSS positive symptom items: delusions, hallucinatory behavior,
conceptual disorganization, or suspiciousness, with at least one of
the two items being delusions or hallucinatory behavior.
2.3. Assessments
The changes in PANSS total Score was the primary efﬁcacy measure.
Change in PANSS Positive, Negative andGeneral Psychopathology symp-
tom subscale scores, the Clinical Global Impression-Severity (CGI-S)
(Guy, 1976), to measure clinical severity, and the Calgary Depression
Scale for Schizophrenia (CDSS), to assess depression (Addington et al.,
1990) were secondary outcome measures. The three scales were
performed at Baseline (day −1) and then two to six hours post-dose
at visits at day 8, day 15, day 22, day 29, day 36 and day 43. The Barnes
Akathisia Scale (BAS; Barnes, 1989) and the Simpson-Angus Scale
(SAS; Simpson and Angus, 1970) were administered at baseline and
six to nine hours after dosing on day 1 and each of the study visit days
listed above. Safety was assessed by comparing adverse events along
with changes from baseline in weight, laboratory values (including pro-
lactin), ECGs, vital signs, and physical examinations (including a brief
neurological exam) on day 15 and 43.
2.4. Data analysis
Sample size for this study was based on a minimum of 80% power
to detect a difference of 5 points between the group receiving
RIS2PIM and the RIS2PBO group in the mean change from baseline
146 H.Y. Meltzer et al. / Schizophrenia Research 141 (2012) 144–152to day 43 in PANSS total score, with the assumption of a within group
standard deviation of 10 points and a two-sided test at the 5% signif-
icance level. A sample size of at least 80 patients per group was there-
fore required.
The primary efﬁcacy variable and each of the secondary efﬁcacy
variables were summarized by visit using descriptive statistics for
continuous data, and using frequency counts and percentages for cat-
egorical data. For each of the secondary efﬁcacy variables, the follow-
ing treatment group comparisons were investigated: RIS2PBO vs.
RIS2PIM and HAL2PBO vs. HAL2PIM. These groups were also com-
pared with RIS6PBO.
As stated in the statistical plan, the primary efﬁcacy measure was
change from baseline to day 43 (endpoint) in mean PANSS total score
using the ITT LOCF population for RIS2PIM and HAL2PIM. For the con-
tinuous secondary efﬁcacy endpoints, differences between the treat-
ment groups were assessed for mean change from baseline to each
visit using an analysis of covariance (ANCOVA) with baseline score
as covariate, and inclusion of treatment, country, and treatment by
country interaction in the model. The treatment by country effect
was tested at an alpha level of 0.10 for the homogeneity of treatment
effect between the two countries. Although treatment comparisons
were made at each visit for the ITT (observed cases [OC] and last ob-
servation carried forward [LOCF]) and per protocol (OC and LOCF)
populations, the primary analysis was the ITT LOCF at day 43. Each
treatment group comparison was tested at an alpha level of 0.05.
For the categorical secondary efﬁcacy endpoints, differences between
treatment groups were assessed at each visit for the ITT (OC and
LOCF) and per protocol (OC and LOCF) populations, using the Cochran
Mantel-Haenszel test stratiﬁed by country. The primary analysis was
the ITT LOCF at day 43. Exploratory efﬁcacy analyses were also
performed.2.5. Determination of plasma levels
PIM, HAL, RIS, and 9-OHRIS levels were determined at days 15 and
43, using high pressure liquid chromatography by Tandem Labs, 1121
East 3900 South, Salt Lake City, UT 84124. The plasma levels of PIM,
HAL, RIS, 9-OHRIS, combined RIS and 9-OHRIS, as well as RIS/9-OHRIS
ratios, were summarized using descriptive statistics for each scheduled
sampling time for all study days by treatment. The effect of PIM on the
RIS and HAL measures was compared by t-test.3. Results
The descriptive and demographic data for the ﬁve groups of pa-
tients are given in Table 1. There were no statistically signiﬁcant dif-
ferences in age, sex, race, BMI, proportion hospitalized at baseline,
all baseline PANSS measures, or CGI, among the ﬁve patient groups.
Fig. 1 provides the patient ﬂow diagram. Of the 607 patients screened,
184 (30.3%) were screen failures, leaving 423 patients (69.7%) who
were randomized to ﬁve treatment groups.Table 1
Baseline characteristics and total PANSS change from baseline at day 43 (ITT/LOCF).
RIS2PBO RIS2PIM RIS6PBO HAL2PBO HAL2PIM
N 77 69 76 77 77
Mean age 39.3 38.6 39.4 40.7 41.6
Percent male 67.5% 69.6% 68.4% 70.1% 76.6%
Baseline PANSS score 87.6 84.8 86.4 86.4 85.5
Standard deviation 13.7 9.7 12.0 11.1 11.8
Day 43 PANSS change −16.3 −23.0 −23.2 −25.1 −21.8
Standard deviation 16.9 14.9 18.8 16.5 14.43.1. RIS2PBO vs RIS2PIM and other treatments
The changes in PANSS Total score for the ﬁve groups between
baseline and subsequent visits are given in Fig. 2a.The changes in
PANSS Positive, Negative, General and Cognitive scores are given in
Table 2. The primary efﬁcacy measure, change from baseline to day
43 (endpoint) in mean PANSS total score (ITT LOCF) between groups,
was statistically signiﬁcant (pb0.0001). The RIS2PIM group achieved
a 23.0-point mean reduction (27.4%) in PANSS total score from base-
line, at day 43, compared to a 16.3 point mean reduction (18.6%) in
PANSS total score in the RIS2PBO group, signiﬁcantly less than that
of the RIS2PIM group (p=0.007). Furthermore, the RIS2PIM group
also had statistically signiﬁcantly greater improvements compared
to the RIS2PBO group for PANSS total score and all its subscales, at
all visits after day 8 (Table 2 and Fig. 2). The improvements in the
PANSS negative symptom (p=0.018), and general psychopathology
scores (p=0.006) at end point were signiﬁcantly greater in the
RIS2PIM compared to the RIS2PBO group. There was a trend for a sim-
ilar advantage for improvement in PANSS positive symptom scale
score (p=0.058) at day 43 (Table 1). The all-cause discontinuation
rate in the RIS2PBO group (50%) as well as that for lack of efﬁcacy
(17.9%; both p=0.05) were signiﬁcantly greater than those for the
RIS2PIM group, as well as those of any for any of the other treatment
groups.
The improvement in PANSS total score at endpoint was also ana-
lyzed based on categorical improvement (≥20% and ≥50%) from
baseline. Ad-hoc analyses using ≥30% and ≥40% PANSS improve-
ment from baseline were also performed. The RIS2PBO and RIS2PIM
rates were signiﬁcantly different, favoring RIS2PIM, at day 43 based
upon ≥20% (p=0.001), ≥40% (p=0.049), and ≥50% (p=0.039)
PANSS improvement criteria. Importantly, the proportions of subjects
meeting these response criteria at endpoint for the RIS2PIM and the
RIS6PBO group for the ITT LOCF sample were not statistically signiﬁ-
cantly different for any of the percentage-improvement levels.
3.2. Early response in the RIS2PIM treatment group compared to other
RIS treatment groups
For the ≥20% PANSS improvement analysis, the improvement in
the RIS2PIM group was signiﬁcantly greater at week 2 (day 15) versus
the RIS2PBO (p=0.002; Fig. 2b). Fifty (72.5 %) of the 69 RIS2PIM sub-
jects met this response criterion by day 43, of whom 31 (62.0%) did so
by two weeks. On the other hand, of the 48 (63.2%) of 76 patients
who responded to RIS6PBO by day 43, only 20 (41.7%) responded
by two weeks. Thus, response was signiﬁcantly more rapid with
RIS2PIM compared to RIS6PBO (p=0.01) group.
Mean CGI-S scores (Fig. 2c) signiﬁcantly improved from baseline
to day 43 in the RIS2PIM group (−1.3 points) compared with the
RIS2PBO group (−0.9 points, p=0.008). The greater improvement
in CGI was observed as early as day 15 (p=0.006) and continued to
endpoint (day 22, p=0.003, day 29, p=0.003, day 36, p=0.002).
3.3. Comparison of change in PANSS scores for all treatment groups
The decrease in PANSS total score from baseline in the RIS6PBO,
HAL2PIM and HAL2PBO groups were not signiﬁcantly different from
each other or from the RIS2PIM group at endpoint (Table 2, Fig. 2).
The improvements from baseline to day 43 in the RIS2PIM group
(−23.0), the RIS6PBO group (−23.2), the HAL2PIM (−21.8), and
the HAL2PBO (−25.1) groups were essentially identical. It is highly
noteworthy that the improvement in PANSS total score from baseline
of the RIS2PIM group was not signiﬁcantly different from that of the
RIS6PBO group at any visit. However, the more rapid response of
the RIS2PIM compared to the RIS6PBO groups was suggested by the
general psychopathology subscale comparison which was close to
signiﬁcant in favor of RIS2PIM versus RIS6PBO at days 15 (p=0.07)
Fig. 1. Patient disposition.
147H.Y. Meltzer et al. / Schizophrenia Research 141 (2012) 144–152and 22 (p=0.07). The mean change from baseline in CGI-S scores was
not signiﬁcantly different for the RIS2PIM and the RIS6PBO groups.
3.4. Efﬁcacy of HAL2PIM and HAL2PBO
PANSS total scores were similarly reduced from baseline to end-
point in the HAL2PIM (−21.8 points, 25.5%) subjects and those treat-
ed with HAL2PBO (−25.1 points, 29.0%, p=0.24), respectively. In
contrast with the results of augmentation of RIS2mg with PIM, there
was no signiﬁcant difference in the improvement in PANSS negative
subscale score between HAL2PIM and HAL2PBO. An exploratory anal-
ysis assessing PANSS total score change from baseline in the HAL2PIM
and RIS6PBO groups showed that both produced similar reductions
from baseline to endpoint (−21.8 points [25.5%)] and −23.2 points
[26.8%]).
A PANSS responder analysis indicated that, at day 43, 63.6% of both
theHAL2PIMand theHAL2PBOgroups achieved at least a 20% reduction
in PANSS total score. Analysis of CGI-S scores demonstrated similar
mean reductions from baseline to endpoint for subjects treated with
HAL2PIM (−1.2 points), HAL2PBO (−1.4 points) and RIS6PBO (−1.2
points), respectively. It is noteworthy that HAL2PBO was as effective
as RIS6PBOwith regard to all efﬁcacymeasures, indicating that even pa-
tients with an acute exacerbation of chronic schizophrenia are respon-
sive to this low dose of HAL.
3.5. Plasma levels of RIS, HAL, and PIM
The mean trough plasma levels of HAL, RIS, 9-OHRIS, the RIS/
9-OHRIS ratio, and PIM levels at days 15 and 43 are given in Tables 3A
and 3B. There were no signiﬁcant differences in RIS or 9-OHRIS levels
or their ratios in the RIS2PBO and RIS2 PIM groups at days 15 or 43.
The RIS and 9-OHRIS levels in the RIS6PB0 groups compared to the av-
erage of the two RIS2 groups were 2.5- and 1.7-fold higher at days 15
and 43, respectively. Thus, co-administration of PIM20mg with either
HAL or RIS did not affect trough HAL, RIS, 9-OHRIS, or combined RIS
plasma concentrations. Similarly, PIM trough concentrations at day 15
or day 43 were not signiﬁcantly different in the HAL2PIM and RIS2PIM
groups (Tables 3A and 3B). Plasma HAL levels at day 43 in those with
≥20% improvement in PANSS Total, with orwithout PIM augmentation,
were not signiﬁcantly different (data not presented).3.6. Tolerability
As shown in Table 4, there were no signiﬁcant differences in mo-
toric tolerability (BAS, SAS) between RIS2PIM, RIS2PBO, and RIS6PBO.
Analysis of the subset of subjects who entered the study with a BAS
score of 0 showed less increase in akathisia with RIS2PIM than
RIS2PBO (0.3 vs. 0.9; p=0.052) at day 43. The HAL2PIM group pro-
duced a decrease of 0.6 points in mean SAS score at day 43 compared
to a decrease of 0.3 points for the HAL2PBO group (p=0.07). A com-
parison to the RIS6PBO group (mean SAS decrease of 0.2 points) also
favored the HAL2PIM group (p=0.06).
3.7. General safety
Treatment-emergent adverse events (TEAEs) were similar among
all treatment groups. The most frequently reported TEAEs were
headache, sedation, nausea, and agitation. Of TEAEs in either PIM
co-therapy group, compared with their respective placebo group(s),
only somnolence, nausea and, to a lesser extent, dyspepsia, diarrhea,
and pain in an extremity had a higher incidence (>2 percentage
point difference) in both co-therapy groups. The incidence of agitation
was greatest in the RIS2PIM group (25.3%) but no subject in either
co-therapy group discontinued treatment due to agitation. No life-
threatening TEAEs or deaths were reported in either co-therapy group.
The most frequent TEAEs leading to discontinuation were psychiatric,
neurological, or gastrointestinal disorders. These did not differ in fre-
quency in the ﬁve groups. There were 25 serious adverse events
(SAEs) in 23 subjects. Four subjects each in the RIS2PIM (5.1%) and the
HAL2PIM group (4.9%) reported SAEs. In comparison, eight (9.6%) sub-
jects in the RIS2PBO group, ﬁve (5.9%) subjects in the RIS6PBO group,
and two (2.4%) subjects in the HAL2PBO group reported SAEs. Weight
gain was notably higher in the RIS6PBO group compared to both
co-therapy groups (Fig. 3a). Mean weight gain from the screening visit
to the ﬁnal visit was 2.11 kg in the RIS6PBO group compared with
1.07 kg in the RIS2PIM group (p=0.05),1.05 kg in the RIS2PBO group,
0.44 kg in the HAL2PIM group, and 0.77 kg in the HAL2PBO group. The
percentage of subjects who gained at least 7% in weight at endpoint
was signiﬁcantly greater in the RIS6PBO (18.9%) compared with the
RIS2PIM group (6.3%; p=0.03). There was no difference in weight
gain between the HAL2PIM and HAL2PBO groups.
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Fig. 2. Therapeutic responses over time as measured by (a) change in PANSS total from
baseline, (b) percent of subjects showing at least 20 % improvement in PANSS total, and
(c) CGI-severity.
Table 3A
Mean levels (ng/ml) of HAL, RIS, 9-0HRIS, RIS/9-OHRIS and PIM Day 15.
DAY 15 Treatment arm
RIS2PBO
(n=62)
RIS2PIM
(n=54)
RIS6PBO
(n=64)
HAL2PBO
(n=63)
HAL2PIM
(n=60)
HAL – – – 0.55 0.57
RIS 0.63 0.56 1.73 – –
9-OHRIS 10.44 8.60 23.25 – –
RIS/9-OHRIS 0.06 0.07 0.07 – –
PIM – 21.1 – – 23.7
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higher in the RIS6PBO group compared to the RIS2PIM or the
HAL2PIM groups (Fig. 3b and c). In a ranked analysis of covarianceTable 2
Changes in PANSS Scores (Mean, SEM) from Baseline to Day 43 (ITT, LOCF).
PANSS
Measure
Treatment Arm
RIS2PBO
(n=77)
RIS2PIM
(n=69)
RIS6PBO
(n=76)
HAL2PBO
(n=77)
HAL2PIM
(n=77)
Total −16.3 (1.9) −23.0 (1.8) −23.2 (2.2) −25.1 (1.9) −21.8 (1.6)
Positive −5.9 (0.6) −7.4 (0.6) −8.1 (0.7) −8.1 (0.6) −6.9 (0.6)
Negative −3.7 (0.6) −5.1 (0.6) −4.9 (0.6) −5.9 (0.6) −5.1 (0.5)
Cognition −2.7 (0.5) −3.4 (0.4) −4.1 (0.5) −4.1 (0.5) −3.6 (0.4)
General −6.7 (1.0) −10.5 (1.0) −10.2 (1.1) −11.1 (1.0) −9.8 (0.8)comparison, the change in prolactin levels from baseline was signif-
icantly greater at day 43 in the RIS6PBO compared to the RIS2PIM
(p=0.0004) and HAL2PIM (pb0.0001) groups. Similarly, mean
serum glucose levels increased signiﬁcantly more in the RIP6PBO
(0.56 mmol/L) than in the RIS2PIM (0.20 mmol/L) group at endpoint
(p=0.02). The mean serum glucose increase at endpoint in the
HAL2PIM group was 0.28 mmol/L. Additionally, shifts from normal
(baseline) to high (endpoint) in SPTT, creatine kinase, SGOT/AST,
and SGPT/ALT were fewer in the co-therapy arms versus the RIS6PBO
group. Normal to high shifts in triglycerides, HDL cholesterol, LDL cho-
lesterol, and total cholesterol were variable and inconsistent among
treatment groups, as were shifts in bilirubin measures. There were no
laboratory, vital sign, or ECG ﬁndings producing safety concerns in the
PIM-treated groups.
4. Discussion
The principal aim of this studywas to determine if a selective 5-HT2A
inverse agonist, PIM, could restore the efﬁcacy of low, sub-effective
doses of representative atypical and typical APDs, in acutely psychotic
chronic schizophrenia patients, along with advantages for side effects
such as weight gain and EPS as the result of the lower doses of the
APDs. With PIM augmentation, RIS2mg had efﬁcacy comparable to
RIS6PBO at 6 weeks and, importantly, was found to be more effective
at day 15. PIM augmentation also potentiated the improvement in neg-
ative symptoms produced by RIS2mg. As predicted, RIS2PIM produced
signiﬁcantly fewer motor and metabolic side effects than RIS6PBO at
endpoint. Unexpectedly, HAL2PBO was as effective as RIS6PBO and
HAL2PIM at all time points. PIM did not potentiate the efﬁcacy of HAL
on any aspect of psychopathology. However, there was some evidence
that PIM augmentation reduced akathisia and other EPS produced by
HAL2mg. There was no evidence that pharmacokinetic differences con-
tributed to these ﬁndings, as PIM did not inﬂuence the levels of RIS,
9-OHRIS, the major metabolite of RIS, the RIS/9-OHRIS ratio, or HAL
levels in plasma.
We compared RIS 6 mg/day, considered the standard RIS dose,
and PBO with what were expected to be sub-effective doses of RIS
and HAL, 2 mg/day (Chouinard et al., 1993; Marder and Meibach,
1994; Nyberg et al., 1999; Potkin et al., 2003; Miller et al., 2004;
Lieberman et al., 2005), combined with a dose of PIM which saturates
brain 5-HT2A receptors (Nordstrom et al., 2008) or with placebo. Sin-
gle oral doses of PIM as low as 10 mg fully saturate brain 5-HT2ATable 3B
Mean levels (ng/ml) of HAL, RIS, 9-0HRIS, RIS/9-OHRIS and PIM day 43.
DAY 43 Treatment Arm
RIS2PBO
(n=39)
RIS2PIM
(n=48)
RIS6PBO
(n=55)
HAL2PBO
(n=55)
HAL2PIM
(n=43)
HAL – – – 0.47 0.58
RIS 0.52 0.67 1.25 – –
9-OHRIS 6.96 5.78 10.88 – –
RIS/9-OHRIS 0.08 0.12 0.12 – –
PIM – 16.3 – – 11.8
Table 4
Extrapyramidal symptoms and akathesia as measured by Simson/Angus Scale (SAS)
and Barnes Akathesia Scale (BAS), respectively.
Treatment arm Treatment day SAS
Mean (SEM)
BAS
Mean (SEM)
RIS2PBO
(n=77)
Baseline
Day 43
0.9 (0.2)
1.0 (0.3)
0.9 (0.2)
1.1 (0.3)
RIS2PIM
(n=69)
Baseline
Day 43
0.8 (0.4)
0.6 (0.2)
0.9 (0.2)
0.6 (0.2)
RIS6PBO
(n=76)
Baseline
Day 43
0.8 (0.2)
0.6 (0.1)
0.9 (0.2)
0.8 (0.2)
HAL2PBO
(n=77)
Baseline
Day 43
1.1 (0.3)
0.8 (0.3)
0.8 (0.3)
0.9 (0.2)
HAL2PIM
(n=77)
Baseline
Day 43
0.9 (0.2)
0.3 (0.1)
1.0 (0.3)
0.7 (0.2)
0
0.5
1
1.5
2
2.5
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(n=62)
RIS2PIM
(n=63)
RIS6PBO
(n=74)
HAL2PBO
(n=70)
HAL2PIM
(n=62)
M
ea
n 
ch
an
ge
 in
 w
ei
gh
t (k
g)
0
0.1
0.2
0.3
0.4
0.5
0.6
RIS2PBO
(n=78)
RIS2PIM
(n=71)
RIS6PBO
(n=80)
HAL2PBO
(n=78)
HAL2PIM
(n=78)
M
ea
n 
ch
an
ge
 in
 s
er
um
 g
lu
co
se
(m
mo
l/l)
-100
0
100
200
300
400
500
600
700
800
RIS2PBO
(n=79)
RIS2PIM
(n=71)
RIS6PBO
(n=79)
HAL2PBO
(n=78)
HAL2PIM
(n=78)
M
ea
n 
ch
an
ge
s 
in
 p
ro
la
ct
in
(ng
/m
l)
(a)
(b)
(c)
Fig. 3. Changes from baseline to day 43 in (a) weight (mean change from baseline to de-
rived endpoint; LOCF post baseline), (b) serum glucose level (mean change from baseline
to derived endpoint; LOCF post baseline), and (c) prolactin level (mean change frombase-
line to day 43). (a) Mean weight gain at end of study compared to baseline. RIS2PIM had
signiﬁcantly less weight gain (p=0.05) than RIS6PBO. (b) Mean change from baseline to
derived endpoint (LOCF post baseline). (c) Mean change from baseline to derived end-
point (LOCF post baseline).
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duced slow wave sleep in older healthy volunteers (Ancoli-Israel et
al., 2011). The improvement at 6 weeks in the RIS6PBO group was
comparable to that in other double-blind, randomized studies of re-
cently hospitalized patients with schizophrenia (Potkin et al., 2003,
2007). The PANSS and CGI-S data conﬁrm previous reports that RIS
1–2 mg/day is sub-effective for the treatment of chronic schizophre-
nia (Kapur et al., 2000; Agid et al., 2007). However, RIS2PIM was su-
perior to RIS2PBO with regard to PANSS total (p=0.0007), PANSS
negative symptoms (p=0.018), PANSS ≥20% (p=0.001) and ≥50%
(p=0.04) responder rates, and the CGI-S score (p=0.008) at end-
point. Additionally, discontinuations due to lack of efﬁcacy were nota-
bly lower in the RIS2PIM (3.8%) compared to the RIS2PBO group
(17.4%) and comparable to that of the RIS6PBO group (4.6%). The re-
sults reported here with regard to improvement in negative symptoms
are consistent with the beneﬁts reported by Akhondzadeh et al. (2008)
from the combination of RIS and ritanserin. The latter results are difﬁ-
cult to interpret because the dose of RIS 6 mg/day would be expected
to fully saturate cortical 5-HT2A receptors (Nyberg et al., 1999).
Ritanserin has moderate potency for 5-HT2B and 5-HT2C receptors
which might have been spared in the patients treated with risperidone
plus placebo (Bonhaus et al., 1995).
The PANSS, but not the CGI-S, data indicated that RIS2PM had a
more rapid onset of action than RIS6PBO, whereas no difference in ef-
ﬁcacy was evident at week six with either measure. While 63.3% of
the subjects in the RIS2PIM group improved in PANSS total by ≥20%
by day 15, this response rate was not present in the RIS6PBO group
until day 29. The response rate for RIS6PBO at day 15 was not signif-
icantly different from that reported in a recent open trial of RIS in
schizophrenia patients, in which the mean modal RIS dose was
~4.6 mg/day (Kinon et al., 2010). Altogether, these results suggest
that RIS2PIM was at least as effective as RIS6PBO and may have an
earlier onset of antipsychotic action.
The HAL treatment results were surprising in that HAL2PBO was as
effective as RIS6PBO but as will be explained, the lack of potentiation
of HAL by PIM is consistent with clinical and preclinical studies. The
‘neuroleptic threshold (NT)’ is deﬁned as the threshold dose for EPS
and efﬁcacy for typical APDs. For chronic schizophrenia patients, the
NT for HAL was reported to be 4.2±2.4 mg/day (McEvoy et al., 1986,
1991). HAL 2 mg/day is one third the lowest HAL dose (6–15 mg/day)
previously used as the active comparator in various randomized con-
trolled trials in schizophrenia (see Hugenholtz et al., 2006). Clinical tri-
als of patients comparable to those in this study have suggested that a
dose of 4 mg/day of HAL is needed to improve psychopathology in
most acutely psychotic, non-treatment resistant patients with schizo-
phrenia (McEvoy et al., 1986, 1991; Zimbroff et al., 1997). Variations
in the type and severity of illness of the patients, and the clinical milieu
in which the trials take place, may lead to shifts in the dose–response
curve that made these historical benchmarks misleading for the pur-
poses of this study.We did not observe an efﬁcacy advantage of HAL2PIM over
HAL2PBO. However, a signiﬁcant advantage of HAL2PIM was demon-
strated for akathisia. SAS scores (p=0.07) and ad-hoc BAS scores
(p=0.08) also tended to show an advantage for HAL2PIM over
HAL2PBO. The differential effect of PIM to potentiate the efﬁcacy of
RIS and not HAL may be related to the recent reports of heterodimers
of 5-HT2A and D2 receptors (Albizu et al., 2011) and 5-HT2A and
mGluR2 receptors (Fribourg et al., 2011). Albizu et al. (2011) ob-
served that the effect of HAL to block MK-801 induced increase in lo-
comotor activity models of antipsychotic activity was reduced but not
eliminated in 5-HT2A receptor knock-out mice. We have reported that
the ability of sub-effective doses of RIS and other atypical APDs to re-
verse the deﬁcit in novel object recognition produced by subchronic
treatment with the NMDAR antagonist, phencyclidine (PCP) is re-
stored by PIM andM100907, another 5-HT2A receptor inverse agonist,
while HAL, with or without PIM, is ineffective in this regard. We have
also reported that the mGlu2/3 agonist LY379268, did not attenuate
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dose of the atypical APDs, clozapine or lurasidone, whose pharmacol-
ogy is similar to that of RIS but not HAL or PIM, LY379268 signiﬁcantly
reversed the PCP-induced NOR deﬁcit. Moreover, the effect of cloza-
pine was blocked by the mGlu2/3 antagonist, LY341495 (Horiguchi
et al., 2011b). The NOR results in this hypoglutamate model of cogni-
tive impairment in schizophrenia are analogous to those found in the
current clinical trial and suggest that the hypoglutamate model may
better reﬂect the underlying pathology in patients with schizophrenia
than do studies in normal rats, such as those reported by Gardell et al.
(2007) in which PIM potentiated the antipsychotic-like actions of
HAL. The inability of PIM to potentiate the efﬁcacy of HAL may also
be a ceiling effect, or may reﬂect important differences in the pharma-
cology of typical and atypical APDs (Meltzer et al., 1989; Meltzer and
Huang, 2008), e.g. the inability of PIM or M100907, another selective
5-HT2A inverse agonist, to potentiate typical APDs, including HAL and
perphenazine, in a rodent cognition model (Snigdha et al., 2010;
Meltzer et al., 2011b).
Consideration of plasma levels of HAL and RIS in relation to re-
sponse in schizophrenia provides another means of assessing wheth-
er HAL2mg or RIS2mg would be expected to be sub-effective. Plasma
levels of HAL and RIS provide a highly accurate index of D2 receptor
occupancy as measured by PET (Kapur et al., 1996). HAL 2 mg/day
produced D2 receptor occupancy in the supposedly optimal range of
53-74% in ﬁrst episode, neuroleptic naïve patients at plasma levels
of 1–1.5 ng/ml (Uchida et al., 2011), whereas plasma levels of
45 ng/ml have been suggested to be necessary for chronic patients
(Hugenholtz et al., 2006). The mean plasma HAL levels in this study
ranged from 0.47 to 0.88 ng/ml, well below the levels noted above.
These results require replication. If conﬁrmed, they would suggest an-
tipsychotic efﬁcacy may be achieved at lower occupancy of D2 recep-
tors than previously thought to be necessary. Striatal D2 receptor
occupancy in patients with schizophrenia produced by RIS has been
shown to be dose-dependent (Kapur et al., 1995, 1996, 1997, 2000).
RIS 3 mg/day produced 72% mean D2 receptor occupancy in ﬁrst epi-
sode or neuroleptic-free schizophrenia patients (Nyberg et al., 1999),
leading to the proposal that RIS 4 mg/day is an optimal dose for more
chronic patients. While RIS 2 mg/day has been reported to produce a
mean 66% D2 receptor occupancy, which is still believed to be within
the optimal range (Kapur et al., 1995) it clearly was a suboptimal dose
in this study.
Whether PIM would potentiate the efﬁcacy of a dose of HAL which
is sub-effective remains to be determined. What may be concluded
from this study is that extensive blockade of 5-HT2A receptors by
PIM does not enhance the efﬁcacy of low dose HAL and that HAL
doses as low as 2 mg/day may be sufﬁcient to treat the psychopathol-
ogy of chronic, as well as ﬁrst episode schizophrenia patients,
experiencing an acute exacerbation. PIM augmentation of HAL2mg
did not shorten the time for control of psychopathology, as it did for
RIS2mg.
The fact that HAL2PBO and HAL2PIM were as effective as RIS6PBO
is consistent with previous reports from this laboratory and others
(Lee et al., 1999; Lieberman et al., 2005; Simon et al., 2009) that for
moderately ill, non-treatment resistant outpatient patients with schizo-
phrenia, there is no difference in improvement in psychopathology be-
tween typical APDs and atypical APDS, even clozapine. However, motor
side effects from even low doses of typical APDs, will increase the risk
for tardive dyskinesia, compared to atypical APDs (Margolese et al.,
2005), providing a strong rationale for preferring treatment with atyp-
ical over typical APDs (Meltzer et al., 2010a).
The more rapid response to RIS2PIM than RIS6PBO is an important
ﬁnding which has to be conﬁrmed in additional studies. If RIS2PIM is
more rapidly effective than higher doses of RIS alone, it might be the
result, in part, of lower D2 receptor occupancy, which, when com-
bined with full 5-HT2A receptor occupancy achieved by the addition
of PIM, can more rapidly produce an optimal restoration of neuralactivity in themesolimbic andmesocortical DA systems than is possible
in the presence ofmore extensive occupancy of pre-andpostsynaptic D2
receptors. We have previously reported that additional D2 receptor
blockade, the results of augmentation with RIS 4–6 mg/day, does not
improve, and may diminish the efﬁcacy of clozapine, a potent 5-HT2A
receptor antagonist, in treatment resistant patients with schizophrenia
(Anil Yagcioglu et al., 2005). Similar results have been reported by
others (Honer et al., 2006). Full D2 DA receptor blockade due to the ad-
dition of HAL also reduced the efﬁcacy of RIS to restore novel object rec-
ognition, a putativemeasure of declarativememory, in rats treatedwith
subchronic PCP (Snigdha et al., 2010). It remains to be determined if
PIM could also lead to more rapid response to other atypical APDs
which share the pharmacology of RIS, e.g. clozapine, lurasidone,
olanzapine, etc.
The safety advantages of RIS2PIM over RIS6PBO groupwere demon-
strated in exploratory analyses comparingmeanweight gain (p=0.05),
>7% weight gain (p=0.03), serum prolactin increases (p=0.0004),
serum glucose increases (p=0.02), and akathisia. There were no
meaningful differences between these two treatments in other safe-
ty measures. As discussed below, HAL2PIM produced fewer EPS than
HAL2PBO. PIM augmentation of sub-effective doses of RIS suggests a
new paradigm for utilizing atypical APDs with pharmacology similar
to RIS, i.e. the use of lower doses of these drugs, in combination with
PIM, to reduce side effects due not only to D2 receptor occupancy
(e.g. EPS and prolactin elevations), but also weight gain, sedation,
and blood pressure regulation, related to other dose-dependent re-
ceptor interactions. A recent review provided evidence that the met-
abolic side effects and weight gain associated with clozapine and
olanzapine are dose-dependent (Simon et al., 2009). Potentiation by
PIM of the ability of lurasidone, olanzapine, quetiapine, risperidone,
and ziprasidone, but not haloperidol, to enhance cortical and hippocam-
pal DA efﬂux in awake freely moving rats and to enhance the ability of
these atypicals to produce acute reversal of the effect of PCP to impair
novel object recognition (Snigdha et al., 2010; Horiguchi et al., 2011a,
2011b; Meltzer et al., 2011b) supports the possibility that the positive
clinical results reported here will extend to other atypical APDs. Unde-
sirable increases in metabolic measures which can contribute to the
shorter longevity of patients with schizophrenia and bipolar disorder
(Tiihonen et al., 2009) might be attenuated with augmentation of
sub-effective doses of atypical APDs by 5-HT2A inverse agonists such
as PIM. If the beneﬁcial effects of augmentation with PIM are conﬁrmed
by further study, it would favorably impact on the risk-beneﬁt consider-
ations concerning these agents, especially clozapine and olanzapine,
which have heavy metabolic burdens at standard doses (Meltzer et al.,
2011a).
These results further conﬁrm the hypothesis that 5-HT2A inverse
agonism is an important principle in the treatment of psychotic disor-
ders such as schizophrenia (Meltzer et al., 1989, 2012; Martin et al.,
1997; Carlsson et al., 1999). They are consistent with evidence from
PET and post-mortem studies of schizophrenia and controls for
non-treatment related alterations in 5HT2A receptors (Meltzer et al.,
2003; Erritzoe et al., 2008) genetic studies (Maier et al., 2008), and
animal models of schizophrenia (Meltzer and Huang, 2008; Moreno
et al., 2011) for the importance of 5-HT2A receptors in the etiology
and treatment of schizophrenia.
Limitations of this study include the lack of a placebo group. Thiswas
not permitted in Brazil. However, the RIS2PBO group served as a pseudo
placebo group because it was sub-effective, permitting the recognition
of the beneﬁcial effects of augmentation with PIM and facilitating com-
parison of RIS2PIM with RIS6mg. An additional arm with 20 mg of PIM
alonewould have provided information on the antipsychotic efﬁcacy of
PIM as a standalone agent in acutely psychotic patients with schizo-
phrenia. In addition, using a lower, sub-effective dose of HAL would
have tested the hypothesis that PIM could enhance the activity of a
sub-effective dose of HAL.We also did not test the ability of PIM to affect
cognition, an important issue which deserves further testing.
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This study demonstrated that the selective 5-HT2A inverse agonist,
PIM, together with a sub-effective RIS dose, was signiﬁcantly more ef-
ﬁcacious than sub-effective RIS alone and produced fewer side effects
than standard dose RIS. PIM did not potentiate HAL2mg, a dose which
in this study, at least, was as effective as a standard dose of RIS but it
did diminish the akathisia produced by HAL. Potentiation of sub-
effective doses of RIS, possibly other atypical APDs, and typical APDs
with PIM should be further studied as a means of reducing dose-
dependent side effects and possibly promoting more rapid onset of
action with atypical APDs.
Role of funding sources
ACADIA funded the clinical trial and data analysis. Other funding sources, such as
donations from the Hintz, Peterson and Weisman families, provided salary support
for H.Y. Meltzer.
Contributors
Drs. Uli Hacksell, David M. Weiner, Kimberly Vanover, and Herbert Y. Meltzer con-
tributed towards the research design. Drs. Daniel P. van Kammen and H. Elkis contrib-
uted towards the execution. Drs. Perry Peters, Herbert Y. Meltzer and Uli Hacksell
contributed towards the data analysis and write up.
Conﬂict of interest
H.Y. Meltzer is a stockholder of ACADIA. He has received grant support in the last
3 years from BioLIne Rx, Cephalon, Dainippon Sumitomo, Eli Lilly, EnVivo, Janssen,
Otsuka, Pﬁzer, and Sunovion. He is, or has been, a consultant to ACADIA, Alkemes,
Astellas, Boehringer Mannheim, Bristol Myers Squibb, Cypress, Janssen, Lundbeck, Ova-
tion, Merck, Novartis, Pﬁzer, Teva, and Valeant (BioVail). The research effort of HYM is
supported, in part, by donations from the Hintz, Peterson and Weisman families.
H. Elkis has received grant support in the last 3 years from Fapesp, Janssen,
Novartis and Roche. He is, or has been, a consultant to Astra-Zeneca, Janssen, Lundbeck,
Merck-Sharp-Dohme, Novartis, Pﬁzer and Roche.
Perry Peters, Kimberly Vanover, Daniel Van Kammen, and David Weiner were em-
ployees of ACADIA at the time this study was conducted. They are no longer employed
by ACADIA.
Uli Hacksell is a stockholder and employee of ACADIA.
Acknowledgements
This study is dedicated to the memory of Mark Brann, Ph.D., deceased, a founder of
ACADIA, whose interest in the role of 5-HT2A inverse agonists in the action of atypical
APDs, led to the discovery of pimavanserin.
The authors thank the patients who participated in this study; the physicians who
cared for them:David Brown, Joao Alberto Campos, Dirceu Zorzetto, LevGertsik, Hamilton
Grabowski, Mary Knesevich, Adam Lowy, Raymond Manning, Morteza Marandi, Ricky
Mofsen, Mario Louza, Irismar Reis de Oliviera, Murray Rosenthal, Sandra Ruschel, Tram
Tran-Johnson, Stephan Volk, andDavidWalling; andMarlisa Anderson, DaunBahr, Robert
E. Davis, Ph.D., Roger Mills, M.D., and Hilde Williams for their individual contributions to
this study.
References
Addington, D., Addington, J., Schissel, B., 1990. A depression rating scale for schizo-
phrenics. Schizophr. Res. 3, 247–251.
Agid, O., Mamo, D., Ginovart, N., Vitcu, I., Wilson, A.A., Zipursky, R.B., Kapur, S., 2007.
Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response — a
double-blind PET study in schizophrenia. Neuropsychopharmacology 32, 1209–1215.
Akhondzadeh, S., Malek-Hosseini, M., Ghoreishi, A., Raznahan, M., Rezazadeh, S.A., 2008.
Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia:
a double-blind randomized placebo-controlled study. Prog. Neuropsychopharmacol.
Biol. Psychiatry 32, 1879–1883.
Albizu, L., Holloway, T., González-Maeso, J., Sealfon, S.C., 2011. Functional crosstalk and
heteromerization of serotonin 5-HT2A and dopamine D2 receptors. Neuropharma-
cology 61, 770–777.
Ancoli-Israel, S., Vanover, K.E., Weiner, D.M., Davis, R.E., Van Kammen, D.P., 2011.
Pimavanserin tartrate, a 5-HT(2A) receptor inverse agonist, increases slow wave
sleep as measured by polysomnography in healthy adult volunteers. Sleep Med.
12, 134–141.
Anil Yagcioglu, A.E., Kivircik Akdede, B.B., Turgut, T.I., Tümüklü, M., Yazici, M.K.,
Alptekin, K., Ertugrul, A., Jayathilake, K., Gögüs, A., Tunca, Z., Meltzer, H.Y., 2005.
A double-blind controlled study of adjunctive treatment with risperidone in schizo-
phrenic patients partially responsive to clozapine: efﬁcacy and safety. J. Clin. Psychia-
try 66, 63–72.
Barnes, T.R., 1989. A rating scale for drug-induced akathisia. Br. J. Psychiatry 154,
672–676.Bonhaus, D.W., Bach, C., DeSouza, A., Salazar, F.H., Matsuoka, B.D., Zuppan, P.,
Chan, H.W., Eglen, R.M., 1995. The pharmacology and distribution of human
5-hydroxytryptamine2B (5-HT2B) receptor gene products: comparison with
5-HT2A and 5-HT2C receptors. Br. J. Pharmacol. 115, 622–628.
Buchanan, R.W., 2007. Persistent negative symptoms in schizophrenia: an overview.
Schizophr. Bull. 33, 1013–1022.
Byne, W., White, L., Parella, M., Adams, R., Harvey, P.D., Davis, K.L., 1998. Tardive dyskine-
sia in a chronically institutionalized population of elderly schizophrenic patients:
prevalence and association with cognitive impairment. Int. J. Geriatr. Psychiatry 13,
473–479.
Carlsson, M.L., Martin, P., Nilsson, M., Sorensen, S.M., Carlsson, A., Waters, S., Waters, N.,
1999. The 5-HT2A receptor antagonist M100907 is more effective in counteracting
NMDA antagonist-than dopamine agonist-induced hyperactivity in mice. J. Neural
Transm. 106, 123–129.
Chouinard, G., Jones, B., Remington, G., Bloom, D., Addington, D., MacEwan, G.W.,
Labelle, A., Beauclair, L., Arnott, W., 1993. A Canadian multicenter placebo-
controlled study of ﬁxed doses of risperidone and haloperidol in the treatment of
chronic schizophrenic patients. J. Clin. Psychopharmacol. 13, 25–40.
Creese, I., Burt, D.R., Snyder, S.H., 1976. Dopamine receptor binding predicts clinical
and pharmacological potencies of antischizophrenic drugs. Science 192, 481–483.
Dean, C.E., Thuras, P.D., 2009. Mortality and tardive dyskinesia: long-term study using
the US National Death Index. Br. J. Psychiatry 194, 360–364.
Erritzoe, D., Rasmussen, H., Kristiansen, K.T., Frokjaer, V.G., Haugbol, S., Pinborg, L.,
Baaré, W., Svarer, C., Madsen, J., Lublin, H., Knudsen, G.M., Glenthoj, B.Y., 2008. Cor-
tical and subcortical 5-HT2A receptor binding in neuroleptic-naive ﬁrst-episode
schizophrenic patients. Neuropsychopharmacology 33, 2435–2441.
Fribourg, M., Moreno, J.L., Holloway, T., Provasi, D., Baki, L., Mahajan, R., Park, G., Adney,
S.K., Hatcher, C., Eltit, J.M., Ruta, J.D., Albizu, L., Li, Z., Umali, A., Shim, J., Fabiato, A.,
MacKerell Jr., A.D., Brezina, V., Sealfon, S.C., Filizola, M., González-Maeso, J.,
Logothetis, D.E., 2011. Decoding the signaling of a GPCR heteromeric complex re-
veals a unifying mechanism of action of antipsychotic drugs. Cell 147, 1011–1023.
Gardell, L.R., Vanover, K.E., Pounds, L., Johnson, R.W., Barido, R., Anderson, G.T.,
Veinbergs, I., Dyssegaard, A., Brunmark, P., Tabatabaei, A., Davis, R.E., Brann, M.R.,
Hacksell, U., Bonhaus, D.W., 2007. ACP-103, a 5-hydroxytryptamine 2A receptor in-
verse agonist, improves the antipsychotic efﬁcacy and side-effect proﬁle of halo-
peridol and risperidone in experimental models. J. Pharmacol. Exp. Ther. 322,
862–870.
Guy, W. (Ed.), 1976. ECDEU assessment manual for psychopharmacology Rev Rock-
ville: Alcohol, Drug Abuse, and Mental Health Administration: DHEW publication
no (ADM), 76–338, pp. 217–222.
Harvey, P.D., Bellack, A.S., 2009. Toward a terminology for functional recovery in
schizophrenia: is functional remission a viable concept? Schizophr. Bull. 35,
300–306.
Honer, W.G., Thornton, A.E., Chen, E.Y., Chan, R.C., Wong, J.O., Bergmann, A., Falkai, P.,
Pomarol-Clotet, E., McKenna, P.J., Stip, E., Williams, R., MacEwan, G.W., Wasan, K.,
Procyshyn, R., 2006. Clozapine and Risperidone Enhancement (CARE) Study
Group. N. Engl. J. Med. 354, 472–482.
Horiguchi, M., Huang, M., Meltzer, H.Y., 2011a. The role of 5-hydroxytryptamine 7
receptors in the phencyclidine-induced novel object recognition deﬁcit in rats.
J. Pharmacol. Exp. Ther. 338, 605–614.
Horiguchi, M., Huang, M., Meltzer, H.Y., 2011b. Interaction of mGlu2/3 agonism with
clozapine and lurasidone to restore novel object recognition in subchronic
phencyclidine-treated rats. Psychopharmacology (Berl) 217, 13–24.
Hugenholtz, G.W., Heerdink, E.R., Stolker, J.J., Meijer, W.E., Egberts, A.C., Nolen, W.A.,
2006. Haloperidol dose when used as active comparator in randomized controlled
trials with atypical antipsychotics in schizophrenia: comparison with ofﬁcially
recommended doses. J. Clin. Psychiatry 67, 897–903.
Ichikawa, J., Li, Z., Dai, J., Meltzer, H.Y., 2002. Atypical APDs, quetiapine, iloperidone,
and melperone, preferentially increase dopamine and acetylcholine release in rat
medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res. 956,
349–357.
Kalkstein, S., Hurford, I., Gur, R.C., 2010. Neurocognition in schizophrenia. Curr. Top.
Behav. Neurosci. 4, 373–390.
Kapur, S., Seeman, P., 2001. Does fast dissociation from the dopamine D(2) receptor ex-
plain the action of atypical antipsychotics?: A new hypothesis. Am. J. Psychiatry
158, 360–369.
Kapur, S., Remington, G., Zipursky, R.B., Wilson, A.A., Houle, S., 1995. The D2 dopamine re-
ceptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a
PET study. Life Sci. 57, 103–107.
Kapur, S., Remington, G., Jones, C., Wilson, A., DaSilva, J., Houle, S., Zipursky, R., 1996.
High levels of dopamine D2 receptor occupancy with low-dose haloperidol treat-
ment: a PET study. Am. J. Psychiatry 153, 948–950.
Kapur, S., Zipursky, R., Roy, P., Jones, C., Remington, G., Reed, K., Houle, S., 1997. The re-
lationship between D2 receptor occupancy and plasma levels on low dose oral hal-
operidol: a PET study. Psychopharmacology (Berl) 131, 148–152.
Kapur, S., Zipursky, R., Jones, C., Remington, G., Houle, S., 2000. Relationship between
dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET
study of ﬁrst-episode schizophrenia. Am. J. Psychiatry 157, 514–520.
Kay, S.R., Fiszbein, A., Opler, L., 1987. The Positive and Negative Syndrome Scale
(PANSS) for Schizophrenia. Schizophr. Bull. 13, 261–276.
Keshavan, M.S., Nasrallah, H.A., Tandon, R., 2011. Neurocognition in schizophrenia.
Schizophr. Res. 127, 3–13.
Kinon, B.J., Chen, L., Ascher-Svanum, H., Stauffer, V.L., Kollack-Walker, S., Zhou, W., Kapur, S.,
Kane, J.M., 2010. Early response to antipsychotic drug therapy as a clinical marker of
subsequent response in the treatment of schizophrenia. Neuropsychopharmacology
35, 581–590.
152 H.Y. Meltzer et al. / Schizophrenia Research 141 (2012) 144–152Kroeze, W.K., Hufeisen, S.J., Popadak, B.A., Renock, S.M., Steinberg, S., Ernsberger, P.,
Jayathilake, K., Meltzer, H.Y., Roth, B.L., 2003. H1-histamine receptor afﬁnity predicts
short-term weight gain for typical and atypical APDs. Neuropsychopharmacology 28,
519–526.
Lee, M.A., Jayathilake, K., Meltzer, H.Y., 1999. A comparison of the effect of clozapine
with typical neuroleptics on cognitive function in neuroleptic-responsive schizo-
phrenia. Schizophr. Res. 37, 1–11.
Leucht, S., Wahlbeck, K., Hamann, J., Kissling, W., 2000. New generation antipsychotics
versus low-potency conventional antipsychotics: a systematic review and meta-
analysis. Lancet 361, 1581–1589.
Li, Z., Ichikawa, J., Dai, J., Meltzer, H.Y., 2004. Aripiprazole, a novel antipsychotic drug,
preferentially increases dopamine release in the prefrontal cortex and hippocam-
pus in rat brain. Eur. J. Pharmacol. 16 (493), 75–83.
Lieberman, J.A., Stroup, T.S., McEvoy, J.P., Swartz, M.S., Rosenheck, R.A., Perkins, D.O.,
Keefe, R.S., Davis, S.M., Davis, C.E., Lebowitz, B.D., 2005. Clinical Antipsychotic Trials
of Intervention Effectiveness (CATIE) Investigators. Effectiveness of APDs in pa-
tients with chronic schizophrenia. N. Engl. J. Med. 353, 1209–1223.
Lüttgen, M., Ogren, S.O., Meister, B., 2005. 5-HT1A receptor mRNA and immunoreactiv-
ity in the rat medial septum/diagonal band of Broca-relationships to GABAergic
and cholinergic neurons. J. Chem. Neuroanat. 29, 93–111.
Maier, W., Mössner, R., Quednow, B.B., Wagner, M., Hurlemann, R., 2008. From genes to
psychoses and back: the role of the 5HT2alpha-receptor and prepulse inhibition in
schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 258 (Suppl. 5), 40–43.
Marder, S.R., Meibach, R.C., 1994. Risperidone in the treatment of schizophrenia. Am.
J. Psychiatry 151, 825–835.
Margolese, H.C., Chouinard, G., Kolivakis, T.T., Beauclair, L., Miller, R., Annable, L., 2005.
Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Inci-
dence and management strategies in patients with schizophrenia. Can. J. Psychia-
try 50, 703–714.
Martin, P., Waters, N., Carlsson, A., Carlsson, M.L., 1997. The apparent antipsychotic ac-
tion of the 5-HT2a receptor antagonist M100907 in a mouse model of schizophre-
nia is counteracted by ritanserin. J. Neural Transm. 104, 561–564.
McEvoy, J.P., Stiller, R.L., Farr, R., 1986. Plasma haloperidol levels drawn at neuroleptic
threshold doses: a pilot study. J. Clin. Psychopharmacol. 6, 133–138.
McEvoy, J.P., Hogarty, G.E., Steingard, S., 1991. Optimal dose of neuroleptic in acute
schizophrenia.A controlled study of the neuroleptic threshold and higher haloper-
idol dose. Arch. Gen. Psychiatry 48, 739–745.
Meltzer, H.Y., 2000. An atypical compound by any other name is still an atypical. Psy-
chopharmacology 148, 16–19.
Meltzer, H.Y., Bobo, W.V., 2006. Interpreting the efﬁcacy ﬁndings in the CATIE study:
what clinicians should know. CNS Spectr. 11 (7 Suppl.), 14–24.
Meltzer, H.Y., Huang, M., 2008. In vivo actions of atypical antipsychotic drug on seroto-
nergic and dopaminergic systems. Prog Brain Res. 172, 177–197.
Meltzer, H.Y., Matsubara, S., Lee, J.C., 1989. Classiﬁcation of typical and atypical APDs on
the basis of dopamine D-1, D-2 and serotonin2 pKi values. J. Pharmacol. Exp. Ther.
251, 238–246.
Meltzer, H.Y., Li, Z., Kaneda, Y., Ichikawa, J., 2003. Serotonin receptors: their key role in
drugs to treat schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 27,
1159–1172.
Meltzer, H.Y., Arvanitis, L., Bauer, D., Rein, W., 2004. Meta-Trial Study Group Placebo-
controlled evaluation of four novel compounds for the treatment of schizophrenia
and schizoaffective disorder. Am. J. Psychiatry 161, 975–984.
Meltzer, H.Y., Bobo, W.V., Lee, M.A., Cola, P., Jayathilake, K., 2010a. A randomized trial
comparing clozapine and typical neuroleptic drugs in non-treatment-resistant
schizophrenia. Psychiatry Res. 177, 286–293.
Meltzer, H.Y., Mills, R., Revell, S., Williams, H., Johnson, A., Bahr, D., Friedman, J.H.,
2010b. Neuropsychopharmacology 35, 881–892.
Meltzer, H.Y., Bonaccorso, S., Bobo, W.V., Chen, Y., Jayathilake, K., 2011a. A 12-month
randomized, open-label study of the metabolic effects of olanzapine and risperi-
done in psychotic patients: inﬂuence of valproic acid augmentation. J. Clin. Psychi-
atry. 72 (12), 1602–1610.
Meltzer, H.Y., Horiguchi, M., Massey, B.W., 2011b. The role of serotonin in the NMDA
receptor antagonist models of psychosis and cognitive impairment. Psychophar-
macology (Berl) 213, 289–305.
Meltzer, H.Y., Massey, B.W., Horiguchi, M., 2012. Serotonin receptors as targets for
drugs useful to treat psychosis and cognitive impairment in schizophrenia. Curr.
Pharm. Biotechnol. 13, 1572–1586.
Miller, A.L., Crismon, M.L., Rush, A.J., Chiles, J., Kashner, T.M., Toprac, M., Carmody, T.,
Biggs, M., Shores-Wilson, K., Chiles, J., Witte, B., Bow-Thomas, C., Velligan, D.I.,
Trivedi, M., Suppes, T., Shon, S., 2004. The Texas medication algorithm project: clin-
ical results for schizophrenia. Schizophr. Bull. 30, 627–647.
Moreno, J.L., Kurita, M., Holloway, T., López, J., Cadagan, R., Martínez-Sobrido, L., García-
Sastre, A., González-Maeso, J., 2011. Maternal inﬂuenza viral infection causesschizophrenia-like alterations of 5-HT2A and mGlu2 receptors in the adult off-
spring. J. Neurosci. 31, 1863–1872.
Morrato, E.H., Cuffel, B., Newcomer, J.W., Lombardo, I., Kamat, S., Barron, J., 2009. Met-
abolic risk status and second-generation antipsychotic drug selection: a retrospec-
tive study of commercially insured patients. J. Clin. Psychopharmacol. 29, 26–32.
Nocjar, C., Roth, B.L., Pehek, E.A., 2002. Localization of 5-HT(2A) receptors on dopamine
cells in subnuclei of the midbrain A10 cell group. Neuroscience 111, 163–176.
Nordstrom, A.L., Mansson, M., Jovanovic, H., Karlsson, P., Halldin, C., Farde, L., Vanover,
K.E., Hacksell, U., Brann, M.R., Davis, R.E., Weiner, D.M., 2008. PET analysis of the 2A
receptor inverse agonist ACP-103 in human brain. Int. J. Neuropsychopharmacol.
11, 163–171.
Nyberg, S., Nordström, A.L., Halldin, C., Farde, L., 1995. Positron emission tomography
studies on D2 dopamine receptor occupancy and plasma antipsychotic drug levels
in man. Int. Clin. Psychopharmacol. 10 (Suppl. 3), 81–85.
Nyberg, S., Eriksson, B., Oxenstierna, G., Halldin, C., Farde, L., 1999. Suggested minimal
effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor oc-
cupancy in schizophrenic patients. Am. J. Psychiatry 156, 869–875.
Potkin, S.G., Saha, A.R., Kujawa, M.J., Carson, W.H., Ali, M., Stock, E., Stringfellow, J.,
Ingenito, G., Marder, S.R., 2003. Aripiprazole, an antipsychotic with a novel mech-
anism of action, and risperidone vs placebo in patients with schizophrenia and
schizoaffective disorder. Arch. Gen. Psychiatry 60, 681–690.
Potkin, S.G., Cohen, M., Panagides, J., 2007. Efﬁcacy and tolerability of asenapine in
acute schizophrenia: a placebo-and risperidone-controlled trial. J. Clin. Psychiatry
68, 1492–1500.
Preda, A., Nguyen, D., Macciardi, F., McMillan, L., Bunney, W.E., Potkin, S.G., 2011. D2 re-
ceptor occupancy is not required for antipsychotic response in schizophrenia: A
randomized clinical trials with M100907, a 5HT2A antagonist. (Dec) Personal
Communication. (Jan 5, 2012).
Schotte, A., Janssen, P.F., Gommeren, W., Luyten, W.H., Van Gompel, P., Lesage, A.S., De
Loore, K., Leysen, J.E., 1996. Risperidone compared with new and reference APDs:
in vitro and in vivo receptor binding. Psychopharmacology 124, 57–73.
Schreiber, R., Brocco, M., Millan, M.J., 1994. Blockade of the discriminative stimulus ef-
fects of DOI by MDL 100,907 and the ‘atypical’ antipsychotics, clozapine and risper-
idone. Eur. J. Pharmacol. 264 (1), 99–102.
Simon, V., Van Winkel, R., De Hert, M., 2009. Are weight gain and metabolic side effects
of atypical antipsychotics dose dependent? A literature review. J. Clin. Psychiatry
70, 1041–1050.
Simpson, G.M., Angus, J.W., 1970. A rating scale for extrapyramidal side effects. Acta
Psychiatr. Scand. Suppl. 212, 11–19.
Snigdha, S., Horiguchi, M., Huang, M., Li, Z., Shahid, M., Neill, J.C., Meltzer, H.Y., 2010.
Attenuation of phencyclidine-induced object recognition deﬁcits by the combina-
tion of atypical APDs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) re-
ceptor inverse agonist. J. Pharmacol. Exp. Ther. 332, 622–631.
Tiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., Haukka,
J., 2009. 11-year follow-up of mortality in patients with schizophrenia: a
population-based cohort study (FIN11 study). Lancet 374, 620–627.
Uchida, H., Takeuchi, H., Graff-Guerrero, A., Suzuki, T., Watanabe, K., Mamo, D.C., 2011.
Predicting dopamine D2 receptor occupancy from plasma levels of APDs: a system-
atic review and pooled analysis. J. Clin. Psychopharmacol. 31, 318–325.
Vanover, K.E., Weiner, D.M., Makhay, M., Veinbergs, I., Gardell, L.R., Lameh, J., Del Tredici,
A.L., Piu, F., Schiffer, H.H., Ott, T.R., Burstein, E.S., Uldam, A.K., Thygesen, M.B.,
Schlienger, N., Andersson, C.M., Son, T.Y., Harvey, S.C., Powell, S.B., Geyer, M.A., Tolf,
B.R., Brann, M.R., Davis, R.E., 2006. Pharmacological and Behavioral Proﬁle of N-(4-
Fluorophenylmethyl)-N(1-methylpiperidin-4-yl)-N’-(4-(2methylpropyloxy)
phenylmethyl)Carbamine (2R,3R)-Dihydroxybutanedioate (2:1) (ACP-103),
a Novel 5-Hydroxytryptamine 2A Receptor Inverse Agonist. J. Pharmacol.
Exp. Ther. 317, 910–918.
Velligan, D.I., Weiden, P.J., Sajatovic, M., Scott, J., Carpenter, D., Ross, R., Docherty, J.P.,
2009. Expert Consensus Panel on Adherence Problems in Serious and Persistent
Mental Illness The expert consensus guideline series: adherence problems in pa-
tients with serious and persistent mental illness. J. Clin. Psychiatry 70 (Suppl. 4),
1–46.
Weiner, D.M., Vanover, K.E., Brann, M.R., Meltzer, H.Y., Davis, R.E., 2003. Psychosis of
Parkinson's disease: serotonin 2A receptor inverse agonists as potential therapeu-
tics. Curr. Opin. Investig. Drugs 4, 815–819.
Wiesel, F.A., Nordström, A.L., Farde, L., Eriksson, B., 1994. An open clinical and biochem-
ical study of ritanserin in acute patients with schizophrenia. Psychopharmacology
(Berl) 114, 31–38.
Zimbroff, D.L., Kane, J.M., Tamminga, C.A., Daniel, D.G., Mack, R.J., Wozniak, P.J.,
Sebree, T.B., Wallin, B.A., Kashkin, K.B., 1997. Controlled, dose–response study
of sertindole and haloperidol in the treatment of schizophrenia. Sertindole
Study Group. Am. J. Psychiatry 154, 782–791.
